Quantcast
Last updated on April 21, 2014 at 1:20 EDT

NCM USA Announces a Technology Development and Supply Agreement with Genentech for the Development of Clinical Imaging Agents Using PET Radiopharmaceuticals

October 26, 2012

NCM USA announced today it has signed a Technology Development and Supply Agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the development of specialty clinical imaging agents using Zr-89 developed by NCM USA.

New York, NY (PRWEB) October 25, 2012

NCM USA announced today it has signed a Technology Development and Supply Agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the development of specialty clinical imaging agents using Zr-89 developed by NCM USA.

Revolutionizing the existing manufacturing of PET, the NCM facility design incorporates full-scale automation, multi-compound processing capability, cGMP compliance, and built-in redundancy.

Using its proprietary automation and innovative technologies, NCM will supply GMP grade PET Radiopharmaceuticals for use as imaging agents in some Genentech clinical trials.

NCM´s NY-based site facilitates the production of specialty radioisotopes that are currently in short supply in the US. “Our ultra-modern facility in New York has allowed us to attract big pharmaceutical companies such as Genentech to develop imaging agents using PET Isotopes. We are pleased that Genentech selected us as their partner in this development,” said Anwer Rizvi, President of NCM.

“While the world of PET has changed, the PET industry continues to function in a single-compound processing, non-proprietary drug environment. We are creating a revolution and now PET customers can have access to efficient, reliable, and quality radiopharmaceuticals. We have elevated the status of PET drug manufacturing to the level that the Pharma industry has enjoyed for many years, ” Mr. Rizvi added.

About NCM USA

NCM is a privately held manufacturer of Positron Emission Tomography (PET) radiopharmaceuticals. Its headquarters are located in Manhattan, New York, and its NYC manufacturing location is in the Bronx. Growing demand for PET Imaging for treatment of cancer, brain disorders and heart disease will require additional PET radiopharmaceutical manufacturing capacity in US. NCM is the future of PET Radiopharmaceutical manufacturing. NCM is elevating the status of PET Drug manufacturing to the level that the Pharma industry has enjoyed for many years.

For more information about NCM USA visit our website: http://www.ncm-usa.com or call (212) 719-2322

Contact

Peter J Webner RT(N),CNMT

Vice President Business Development

NCM USA

917.295.2955 Cell

866.875.3868 Fax

NCM USA

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb10052564.htm


Source: prweb